Tomáš Koky

EP447 - ECE_1385 - Associations between DXA-derived parameters of body composition and bone mass density in patients with T2DM and metabolic dysfunction-associated steatotic liver disease

Martin Kaško, Emil Fraenkel, Tomáš Koky, Jana Figurová et autres

Abstract Introduction Metabolic dysfunction-associated steatotic liver disease (MASLD) appears to be associated with changes in bone mineral density (BMD) and fracture rate; however, the current data are ambiguous. The relationship between MASLD and bone metabolism remains controversial regarding the protective effect of …

sk, no (code pays fourni par la source)

Small dense low-density lipoprotein in primary biliary cholangitis: Independent association with metabolic syndrome

Tomáš Koky, Sylvia Dražilová, Martin Janicko, Martin Harhovsky et autres

BACKGROUND Primary biliary cholangitis (PBC) is frequently associated with cholestasis-driven hypercholesterolemia characterized by lipoprotein X accumulation. Despite markedly elevated cholesterol levels, cardiovascular risk in PBC is not consistently increased, suggesting that conventional lipid parameters may inadequately reflect true atherogenic burden. Small dense …

sk (code pays fourni par la source)

Second-line treatment of primary biliary cholangitis: To whom, which molecule, and when

Sylvia Dražilová, Péter Jarcuska, Tomáš Koky, Martin Harhovsky et autres

Ursodeoxycholic acid (UDCA) is the first-line treatment of primary biliary cholangitis (PBC). Approximately two-thirds of patients have a biochemical response to UDCA, but only one-third of treated patients achieve a complete biochemical response. UDCA nonresponse is associated with hepatic decompensation and higher …

sk (code pays fourni par la source)

Epidemiology of Alcohol-Associated Hepatitis: A Systematic Review of Population-Based Studies

Jakub Gazda, Tomáš Koky, Aleksandra Robinska, Na Bo et autres

sk, us, is, cl (code pays fourni par la source)

SAT-305 Metabolic syndrome drives small dense low-density lipoproteins in primary biliary cholangitis: a lipoprint-based analysis

Tomáš Koky, Sylvia Drazilova, Martin Janicko, Slavomira Komarova et autres

ROZHODOVANIE O NEZAHÁJENÍ A UKONČENÍ ŽIVOT UDRŽUJÚCEJ LIEČBY: JUDIKATÓRNY POHĽAD

Tobiáš Pacák, Tomáš Koky

Článok sa venuje problematike medicínsky márnej liečby a jej významu v pri rozhodovaní o nezahájení alebo ukončení život udržiavajúcej terapie. Článok pojednáva o základných medicínskych, etických a právnych východiskách, ktoré formujú súčasné chápanie márnosti, vrátane posunu od kvantitatívnych kritérií k hodnotovo orientovanému …

sk (code pays fourni par la source)

Associations between DXA-derived parameters of body composition and bone mass density in patients with T2DM and metabolic dysfunction-associated steatotic liver disease: a cross-sectional study

Emil Fraenkel, Martin Kaško, Tomáš Koky, Ivica Lazúrová

BACKGROUND: ), and DXA-derived BMD indices in the European population. METHODS: 156 patients, 95 females and 61 males, aged 33-78 years, treated for T2DM and MASLD with oral antidiabetic medication, were included in this cross-sectional study. Subgroup analyses were conducted by sex, …

sk (code pays fourni par la source)

Metabolic syndrome and its individual components but not MASLD are associated with advanced fibrosis in primary biliary cholangitis

Sylvia Drazilova, Tomáš Koky, Martin Janicko, Marek Brenišin et autres

Background: The degree of coincidence and interaction between primary biliary cholangitis (PBC) on the one hand and metabolic syndrome (MetS) or metabolic dysfunction-associated steatotic liver disease (MASLD) on the other is unknown. Objectives: The aim of the study was to evaluate the …

sk (code pays fourni par la source)

Adipokine profiles reflect metabolic dysfunction but not fibrosis in patients with primary biliary cholangitis

Tomáš Koky, Sylvia Dražilová, С.Г. Комарова, Marian Macej et autres

BACKGROUND: Primary biliary cholangitis (PBC) is a rare, nonsuppurative cholestatic disease that affects the small intrahepatic bile ducts. If not adequately managed, it may progress to liver cirrhosis and hepatocellular carcinoma. Only a few studies have explored the impact of cardiometabolic risk …

sk (code pays fourni par la source)

Early assessment of treatment response in primary biliary cholangitis: key to timely management

Tomáš Koky, Sylvia Dražilová, Martin Janíčko, Dominika Toporcerová et autres

AIM: The aim of our study was to explore predictive factors associated with compete biochemical response (CBR) in primary biliary cholangitis (PBC) patients treated with ursodeoxycholic acid (UDCA) at month 12 and at last check-up; CBR was defined as both normal bilirubin …

sk (code pays fourni par la source)

Associations between DXA-derived parameters of body composition and metabolic dysfunction-associated steatotic liver disease in patients with T2DM and prediabetic states

Emil Fraenkel, Tomáš Koky, Samuel Štellmach, Ivica Lazúrová

BACKGROUND: Sarcopenic obesity is closely related to metabolic dysfunction-associated steatotic liver disease (MASLD), but the independent contributions of lean mass and fat mass components to MASLD are not well understood. Our study aimed to evaluate the relationship between the dual-energy X-ray absorptiometry …

sk (code pays fourni par la source)

THU-366 Early assessment of treatment response in primary biliary cholangitis: key to timely management

Tomáš Koky, Sylvia Dražilová, Martin Janicèko, Dominika Toporcerová et autres